Volume | 0.00 |
|
|||||
News | - | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sigyn Therapeutics Inc (QB) | SIGYD | OTCMarkets | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.75 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
0 | 0.00 | - | 3.00 - 6.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 4.75 | USD |
Sigyn Therapeutics Inc (QB) Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 210.07M | 44.22M | 8.63M | - | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sigyn Therapeutics (QB) News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SIGYD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
3 Months | 6.00 | 6.00 | 4.75 | 5.09 | 352 | -1.25 | -20.83% |
6 Months | 3.00 | 6.00 | 3.00 | 4.97 | 310 | 1.75 | 58.33% |
1 Year | 3.00 | 6.00 | 3.00 | 4.97 | 310 | 1.75 | 58.33% |
3 Years | 3.00 | 6.00 | 3.00 | 4.97 | 310 | 1.75 | 58.33% |
5 Years | 3.00 | 6.00 | 3.00 | 4.97 | 310 | 1.75 | 58.33% |
Sigyn Therapeutics (QB) Description
Sigyn Therapeutics is a development-stage company focused on creating therapeutic solutions to address unmet needs in global health. Sigyn Therapy, the Companys lead product candidate, is a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders that are not addressed with approved drug therapies. Candidate treatment indications for Sigyn Therapy include chronic inflammation and endotoxemia in end-stage renal disease patients, sepsis (leading cause of hospital deaths), community acquired pneumonia (a leading cause of death among infectious diseases), and emerging pandemic threats. The Company's development pipeline includes a cancer treatment system comprised of ChemoPrep to enhance the delivery of FDA approved chemotherapeutic agents and ChemoPure to reduce chemotherapy toxicity. |